SAB Biotherapeutics, Inc. (SABS) — Financial statements
Income statement, balance sheet, and cash flow for SAB Biotherapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00↓100.0% | 1↓40.9% | 2↓90.6% | 24↓60.7% | 61 | |
| Cost of Revenue | 3↓35.7% | 5↑28.0% | 4↑13.8% | 3↑99.0% | 2 | |
| Gross Profit | -3↑11.2% | -3↓130.4% | -2↓107.3% | 21↓65.2% | 59 | |
| Operating Expenses | ||||||
| R&D Expenses | 34↑13.9% | 30↑82.7% | 17↓54.7% | 36↓36.3% | 57 | |
| General & Administrative Expenses | 15 | 0.00↓100.0% | 24↑45.3% | 16↓4.1% | 17 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 15↑57.4% | 9↓61.0% | 24↑45.3% | 16↓4.1% | 17 | |
| Other Expenses | -3 | 0.00↑100.0% | -4↓13.8% | -3↓99.0% | -2 | |
| Operating Expenses | 46↑16.3% | 39↑7.9% | 37↓26.2% | 50↓31.8% | 73 | |
| Total Costs & Expenses | 49↑10.7% | 44↑9.7% | 40↓23.7% | 53↓28.9% | 74 | |
| Operating Results | ||||||
| Operating Income | -49↓14.1% | -43↓12.7% | -38↓31.7% | -29↓115.9% | -13 | |
| Depreciation & Amortization | 3↓35.7% | 5↑28.0% | 4↑13.8% | 3↑99.0% | 2 | |
| EBITDA | 17↑157.2% | -29↑24.0% | -38↓152.2% | -15↑0.5% | -15 | |
| EBIT | 14↑140.0% | -34↑19.3% | -42↓127.4% | -18↓9.3% | -17 | |
| Interest & Other Income | ||||||
| Net Interest Income | 1↑23.1% | 0.97↑258.8% | 0.27↑216.7% | -0.23↑14.8% | -0.27 | |
| Interest Income | 1↑11.4% | 1↑119.8% | 0.58↑723.1% | 0.07↑207.5% | 0.02 | |
| Interest Expense | 0.24↓24.4% | 0.32↑1.0% | 0.32↑4.5% | 0.30↑2.4% | 0.29 | |
| Non-Operating Income | -62↓584.7% | -9↓339.9% | 4↑136.2% | -11↓403.8% | 3 | |
| Other Income / Expenses | 62↑606.7% | 9↑313.8% | -4↓140.4% | 10↑372.0% | -4 | |
| Income Before Tax | 13↑138.9% | -34↑19.2% | -42↓125.5% | -19↓9.2% | -17 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00↓100.0% | 0.03 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 13↑138.9% | -34↑19.2% | -42↓125.1% | -19↓9.3% | -17 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 13↑138.9% | -34↑19.2% | -42↓125.1% | -19↓9.3% | -17 | |
| Bottom-Line Net Income | -49↓42.9% | -34↑19.2% | -42↓125.1% | -19↓9.3% | -17 | |
| EPS (Basic) | 0.22↑106.0% | -3.68↑51.8% | -7.64↓77.3% | -4.31↓9.4% | -3.94 | |
| EPS (Diluted) | -0.79↑78.5% | -3.68↑51.8% | -7.64↓77.3% | -4.31↑31.6% | -6.30 | |
| Weighted Average Shares | 19↑108.5% | 9↑67.8% | 6↑26.9% | 4↑0.1% | 4 | |
| Weighted Average Diluted Shares | 61↑562.3% | 9↑67.8% | 6↑26.9% | 4↑59.2% | 3 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.